BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Research

Bayer Submits New Drug Application to FDA for Elinzanetant, a Novel Non-Hormonal Treatment for Menopausal Hot Flashes

The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency...

August 02, 2024 | News

Biosyngen and A*STAR Forge Strategic Alliance to Advance Autoimmune Therapies

Biosyngen has announced a strategic collaboration with Singapore's Agency for Science, Technology and Research (A*STAR) to enhance autoimmune the...

August 02, 2024 | News

Sirnaomics Forms Joint Venture with Gore Range Capital to Propel RNAi Therapeutics into Aesthetic Medicine

Sirnaomics Ltd. (the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical co...

August 01, 2024 | News

SCRI and CADENCE Partner with Clinical Research Malaysia to Strengthen Clinical Research in Singapore and Malaysia

The Singapore Clinical Research Institute (SCRI), together with its sister programme, the Cardiovascular Disease National Collaborative Enterprise (CADENCE...

July 31, 2024 | News

NCCN Enhances Partnership with Medlive to Expand Oncology Guidelines Access in China

United States-based National Comprehensive Cancer Network strengthens relationship with Chinese medical platform Medlive to broaden access to eminent oncol...

July 31, 2024 | News

Menarini Group Announces Positive Phase 3 Trial Results for Obicetrapib in Lowering LDL-C

-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically ...

July 30, 2024 | News

Akeso's Ivonescimab sBLA Accepted by NMPA for First-Line Treatment of PD-L1 Positive NSCLC

Akeso (9926.HK) is delighted to announce that the supplemental biologics license application (sBLA) for its independently developed, world's first-in-class...

July 30, 2024 | News

PolyU Researchers Discover Key Mechanism in Eye Pressure Regulation for Glaucoma Treatment

Glaucoma is one of the leading causes of visual impairment and blindness. According to statistics from the Hospital Authority, in Hong Kong, three out of e...

July 26, 2024 | News

Ractigen Therapeutics' RAG-18 Receives FDA Rare Pediatric Disease Designation for Duchenne Muscular Dystrophy

Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, announced that the U.S. Food and Drug Administration (FDA) has ...

July 26, 2024 | News

Sirnaomics Completes IND-Enabling Studies for siRNA Therapeutic STP125G Targeting ApoC3

Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”),...

July 24, 2024 | News

Duke-NUS Launches LIVE Ventures: S$20M to Commercialize Academic Research

Duke-NUS Medical School launched LIVE Ventures, a S$20 million incubation programme designed to catalyse the commercialisation of innovative acad...

July 22, 2024 | News

GCCL Launches R&D Division to Bolster Biosimilar and Clinical Trial Analysis Services

Newly established R&D division this year is expected to provide full-scale in-house R&D in addition to clinical sample analysis Including blockb...

July 17, 2024 | News

Full-Life Technologies and SK Biopharmaceuticals Ink $571.5 Million Deal for Exclusive Rights to Radiopharmaceutical FL-091

Full-Life Technologies ("Full-Life"), a fully integrated global radiotherapeutics company, announced that it has entered into a license agreement wit...

July 17, 2024 | News

Biosyngen's Groundbreaking CAR-T Therapy BRG01 Approved for Phase II Clinical Trial in China

Biosyngen, a leading biotechnology company focused on the development of innovative cell therapies, recently announced that the Center for Drug Evaluation ...

July 17, 2024 | News

Stay Connected